Chemoprevention of skin cancer in xeroderma pigmentosum.
Xeroderma pigmentosum is a rare recessive disease with sun sensitivity, increased freckling and defective DNA repair. Xeroderma pigmentosum patients have more than a 1000-fold increased risk of developing skin cancer including basal cell carcinoma, squamous cell carcinoma and melanoma. We studied chemoprevention of new skin cancers with oral retinoids in xeroderma pigmentosum patients who had multiple skin cancers. Xeroderma pigmentosum patients were cleared of all pre-existing tumors surgically and then treated with high dose (2 mg/kg/day) oral isotretinoin (13-cis retinoic acid, Accutane) for two years and then for one year off treatment. Patients were examined at regular intervals for new tumor formation and for side effects. Five xeroderma pigmentosum patients had a total of 121 basal or squamous cell carcinomas in 2 years before treatment and only 25 tumors during 2 years of treatment. The tumor frequency increased 8.5-fold after the drug was discontinued (New Engl J Med 318: 1633-1637, 1988). Toxicity (cutaneous, triglyceride, liver-function or skeletal abnormalities) prompted subsequent use of a low dose protocol. Patients were treated initially with 0.5 mg/kg/day oral isotretinoin and the dose was increased sequentially to 1.0 or 1.5 mg/kg/day. We found that toxicity was less with the lower doses. The lowest effective, least toxic dose varied among the xeroderma pigmentosum patients.
Kraemer
K H
KH
Laboratory of Molecular Carcinogenesis, National Cancer Institute, Bethesda, MD 20892.
DiGiovanna
J J
JJ
Peck
G L
GL
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002280:Basal Cell Carcinoma / Q000150:complications / Q000517:prevention & control; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000517:prevention & control; D002648:Child; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000150:complications / Q000517:prevention & control*; D014983:Xeroderma Pigmentosum / Q000150:complications* / Q000473:pathology
D015474:Isotretinoin